Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01951157 · ClinicalTrials.gov registry record · Phase 2

A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients

A Phase 2 study of Non-small Cell Lung Cancer (NSCLC), sponsored by PharmaMar.

Completed
Registry status
Phase 2
Development phase
69
Enrollment target
1
Study location

NCT01951157 is a Phase 2 study of Non-small Cell Lung Cancer (NSCLC) that has completed, run by PharmaMar. The registered enrollment target is 69 participants, below the 288-participant average among 58 other Non-small Cell Lung Cancer (NSCLC) trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01951157, a Phase 2 study of Non-small Cell Lung Cancer (NSCLC), has completed, sponsored by PharmaMar.

COMPLETED
Registry status
Phase 2
Development phase
69 participants
Enrollment target
1
Study location

Study Summary

A clinical study of lurbinectedin(PM01183) alone or in combination with gemcitabine in comparison to docetaxel for the treatment of unresectable non-small cell lung cancer (NSCLC)patients

Conditions Studied

Non-small Cell Lung Cancer (NSCLC)

Interventions

  • DRUG Docetaxel
  • DRUG Gemcitabine
  • DRUG Lurbinectedin (PM01183)

Study Locations (1)

New York

  • - New York

Trial Details

FieldValue
Enrollment Target 69 participants
Start Date 2013-09-11
Est. Completion 2016-11
Phase Phase 2

Sponsor

PharmaMar

32 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01951157

The ClinicalTrials.gov registry entry for NCT01951157 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 288-participant average among 58 other Non-small Cell Lung Cancer (NSCLC) trials with a reported enrollment target (76% lower). The listed sponsor is PharmaMar, which has 32 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Non-small Cell Lung Cancer (NSCLC) appearing as the primary indexed condition, and to 3 interventions - of which Docetaxel is the first listed.

NCT01951157 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT01951157 about?

NCT01951157 is a clinical study titled "A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients". A clinical study of lurbinectedin(PM01183) alone or in combination with gemcitabine in comparison to docetaxel for the treatment of unresectable non-small cell lung cancer (NSCLC)patients

What is the current status of trial NCT01951157?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 69 participants. The study started on 2013-09-11. Estimated completion is 2016-11.

What conditions does trial NCT01951157 study?

This clinical trial studies the following conditions: Non-small Cell Lung Cancer (NSCLC).

What interventions are being tested in trial NCT01951157?

The interventions under investigation include: Docetaxel (DRUG), Gemcitabine (DRUG), Lurbinectedin (PM01183) (DRUG).

Who is sponsoring clinical trial NCT01951157?

This trial is sponsored by PharmaMar, which has 32 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01951157 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non-small Cell Lung Cancer (NSCLC)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Non-small Cell Lung Cancer (NSCLC)

All registered trials for this condition

New York

All trials with a study site in New York

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.